Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach

Sagar Baragea, A. Karthica, Rohit Bavib,c, Neetin Desaid, Raj Kume, Vikas Kumarf and Keun Woo Lee

Aamity Institute of Biotechnology, Amity University, Mumbai, Maharashtra, India; b State Key Laboratory of Natural Medicines, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China; c School of Chemical Sciences, Punyashlok Ahilyadevi Holkar Solapur University, Solapur, Maharashtra, India; d DDSOS, NMIMS University, Mumbai, Maharashtra, India; e Department of Biotechnology and Bioinformatics, Jaypee University of Information Technology, Waknaghat, Solan, Himachal Pradesh, India; f Division of Life Science, Division of Applied Life Science (BK21 Plus), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Research Institute of Natural Science (RINS), Gyeongsang National University (GNU), Jinju, Republic of Korea

Communicated by Ramaswamy H. Sarma

ABSTRACT
The World Health Organization has declared COVID-19 as a global health emergency. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlights an urgent need for therapeutics. Here, we have employed a series of computer-aided drug repurposing campaign to discover inhibitors of RNA dependent RNA polymerase (RdRp) and Nsp15/EndoU. Subsequently, MD simulation has been performed to observe dynamic behavior of identified leads at the active site of RdRp and Nsp15. We successfully identified novel lead molecule such as Alectinib for RdRp while Naldemedine and Ergotamine for Nsp15. These lead molecules were accommodated in the active site of the enzyme and stabilized by the networks of the hydrogen bond, pi type and hydrophobic interaction with key residues of either target. Interestingly, identified compounds show molecular mimicry in terms of molecular interactions with key residues of RdRp and Nsp15 essential for catalysis and substrate interaction. Previously, Alectinib, Naldemedine and Ergotamine were used as drug in different diseases might be repurposed against selected protein targets of COVID19. Finally, we propose that the identified inhibitors represent a novel lead molecule to design a more effective inhibitor to stop the progress of pathogen.

1. Introduction
Coronaviruses (CoVs) is an RNA virus belonging to subfamily Coronavirinae within the family Coronaviridae, which infects humans, birds and mammals (Gorbalenya et al., 2004; Snijder et al., 2003). It was first identified in the Wuhan city of Hubei province of China during the epidemic outbreak in 2019 and is now designated as COVID-19. Electron microscopic image shows a spike-like projection on the outer surface of the virus, giving it crown-like shape, hence the name (Richman et al., 2002). The World Health Organization has declared COVID-19 as a global health emergency. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and highlights an urgent need for therapeutics. Here, we have employed a series of computer-aided drug repurposing campaign to discover inhibitors of RNA dependent RNA polymerase (RdRp) and Nsp15/EndoU. Subsequently, MD simulation has been performed to observe dynamic behavior of identified leads at the active site of RdRp and Nsp15. We successfully identified novel lead molecule such as Alectinib for RdRp while Naldemedine and Ergotamine for Nsp15. These lead molecules were accommodated in the active site of the enzyme and stabilized by the networks of the hydrogen bond, pi type and hydrophobic interaction with key residues of either target. Interestingly, identified compounds show molecular mimicry in terms of molecular interactions with key residues of RdRp and Nsp15 essential for catalysis and substrate interaction. Previously, Alectinib, Naldemedine and Ergotamine were used as drug in different diseases might be repurposed against selected protein targets of COVID19. Finally, we propose that the identified inhibitors represent a novel lead molecule to design a more effective inhibitor to stop the progress of pathogen.

CONTACT Sagar H. Barage sagarbarage@gmail.com Amity Institute of Biotechnology, Amity University, Mumbai - Pune Expressway, Bhatan, Post-Somatne, Panvel, Maharashtra 410206, India
*All author equally contributed.

ARTICLE HISTORY
Received 4 June 2020
Accepted 19 October 2020

KEYWORDS
RdRp; Nsp15; homology modeling; drug repurposing; virtual screening

Supplemental data for this article can be accessed online at https://doi.org/10.1080/07391102.2020.1841026.
in recognition, attachment and entry of virus in the host cell (Belouzard et al., 2012; Ibrahim et al., 2019). The replicase-transcriptase complex consists of 16 non-structural proteins (Nsp1-16) that are auto-proteolytically cleaved by a single Orf encoded polyprotein. RdRp/Nsp12 is a unique class of nucleic acid polymerases encoded by RNA viruses. RdRp is a catalytic core forming a human right-hand design consisting of thumb, fingers and palm domains (Ago et al., 1999; Bressanelli et al., 1999; Hansen et al., 1997; Lesburg et al., 1999). The fingers and palm domains of RdRP are the most conserved parts and consist of 7 conserved polymerase catalytic motifs, which are responsible for the catalysis of only RNA (Elfiky, 2020; Elfiky & Azzam, 2020; Jia & Gong, 2019). The functional part of RdRP is fused with the catalytic part resulting in the diversity of the whole structure and its regulatory mechanism.

On the other hand, Nsp15 is also a non-structural protein of coronavirus and is recognized as an endoribonuclease (EndoU; Bhardwaj et al., 2004; Ivanov et al., 2004). Coronavirus does not require EndoU/Nsp15 activity for the synthesis of RNA (Deng & Susan, 2018; Deng et al., 2019). It has been proved that viruses with catalytic mutant versions of Nsp15 trigger elevated interferon response and PKR-dependent apoptosis (Deng et al., 2017; Kang et al., 2007; Kindler et al., 2017). Nonetheless, Nsp15 activity plays an essential role in evading host sensing of viral dsRNA (Deng et al., 2017, 2019; Kindler et al., 2017). However, inactivating Nsp15 catalytic activity showed rapid clearance of infectious virus from spleen and liver of infected mice, and macrophage showed early induction of type-1 interferon in the virus-infected mice. Protective immune response was also generated in the infected mice, where Nsp15 catalytic activity was inactivated. Thus, RdRPs and Nsp15 are attractive targets for the development of antiviral therapy (Machitani et al., 2020; Deng & Susan, 2018; Wu et al., 2020). The present study aims to identify novel inhibitor molecules against RdRp and Nsp15 targets. In this respect, we predicted 3D structures of RdRps and Nsp15 of COVID-19, followed by stereochemical validation to check the quality of the predicted model. Subsequently, we screened chemical libraries of 3277 compounds (1355 FDA approved drugs and 1922 world not FDA) obtained from ZINC database to identify novel inhibitory molecules against RdRp and Nsp15 using a virtual screening approach. Subsequently, MD simulation has been performed on top two complexes of RdRp and Nsp15. We successfully identified novel lead molecule such as Alectinib for RdRp while Naldemedine and Ergotamine for Nsp15. These lead molecules will provide a detailed framework to understand the nature and selectivity of ligand and may help in the development of safe and effective inhibitors against RdRp and Nsp15.

2. Methods

2.1. Homology modeling of RNA-dependent RNA polymerases (RdRPs) and Nsp15

The complete sequences of RdRP (Acc. No: YP_009725307) and Nsp15 (Acc. No: YP_009725310) were retrieved from the NCBI coronavirus2 data hub. The template search was performed using NCBI’s BLASTp program against a protein data bank (Altschul et al., 1997). The blast search gave hits with significant identity against query protein sequences. The SARS-coronavirus structure of Nsp12 complexed with NSP7 and NSP8 has a 96% identity with RdRp (PDB ID: 6NUR; Kirchdoerfer & Ward, 2019). Whereas, the crystal structure of Nsp15 of SARS-COV shows 88% identity with Nsp15 (PDB ID: 2OZK; Joseph et al., 2007). These crystal structures were used as a template to predict homology models of RdRp and Nsp15. In total, 20 homology models were generated for RdRp and Nsp15 using Modeller 9.23 as per previous studies (Barage et al., 2018; Elmezayen et al., 2020; Sali & Blundell, 1993). Among 20 models, the top model of each structure was selected based on the DOPE score (Shen & Sali, 2006). The structural validation and characterization of the predicted models were performed using PROCHECK (Laskowski et al., 1993) and PROSA-Web Z-Score (Wiederstein & Sippl, 2007).

2.2. Preparation of ligand dataset

The FDA approved, and the world not FDA datasets of compounds were retrieved from the ZINC database. Only purchasable compounds from FDA approved (1355 compounds), and the world not FDA (1922 compounds) were extracted from the ZINC database (Sterling & Irwin, 2015). The world not FDA drug dataset consist drug approved by major national regulatory agencies other than FDA. Both datasets were merged and submitted to the FROG2 server for 3D conformation generation (Miteva et al., 2010). In total, 3277 compounds 3D conformations were minimized using the MMFF94 force field and the steepest descent optimization algorithm implemented in the PyRx tool (Dallakyan & Olson, 2015). The minimized structures of all the ligands were converted into pdbqt format compatible for autodock.

2.3. Target preparation and virtual screening

The predicted models of RdRP and Nsp15 were prepared for docking using AutoDock Tool 1.5.6 (Morris et al., 2009). A well-established docking protocol was used in the present study as per previous studies (Barage et al., 2017; Meshram et al., 2020). The protonation states and Kollman united atom charges were assigned to receptor atoms using the Autodock tool 1.5.6. Then, both the structures were loaded in PyRx and converted into pdbqt format using make macromolecule option of PyRx (Dallakyan & Olson, 2015). The residues are known to play an essential role in catalytic activity, and substrate interaction of RdRp and Nsp15 were treated as flexible residues. The RdRp residues Val557, Asp623, Thr680 and Asn691, are the active site residues and are found conserved in the CoV family as per the previous literature (Kirchdoerfer & Ward, 2019; Jia & Gong, 2019). Whereas, the residues His 234, His 242, His 249 and Lys 289 contributes in the catalytic activity of Nsp15 (Joseph et al., 2007). These active site residues of RdRp and Nsp15 were treated as flexible, and the grid box was set to $50 \times 52 \times 62$ and...
The grid box was centered on selected flexible residues and leaving adequate space for translation (0.25 Å) and rotation (5 Å) of the ligand with 0.375 Å grid spacing. The 10 docking runs were performed for each ligand. The maximum number generation and individual population size were set to 27,000 and 150, respectively. All other parameters were kept to their default values. The generated docked conformation was ranked by predicted binding free energy. The top 10 ligand molecules were shortlisted based on their binding free energy. The binding mode and molecular interaction of the top 10 ligands were analyzed. Subsequently, the conformational clustering was performed on the top 2 ligand conformation with root mean square deviation (RMSD) tolerance 1.5 Å. The top two ligand molecules for RdRp and Nsp15 were selected from the highest populated cluster with the lowest binding energy. The obtained docked complexes were analyzed for its molecular interactions and subjected for MD simulation.

2.4. Molecular dynamics simulations

Molecular dynamics (MD) simulation was performed to study the dynamic behavior of protein ligand complex by applying CHARMM27 (Van Der Spoel et al., 2005) force field implemented in GROMACS 5.0.7 package. SwissParam was used to generate the topology files for ligands (Zoete et al., 2011). The system was solvated in the cubic box of TIP3P water model. Na⁺ counter ions were added to neutralize the negatively charged system. The system was energy minimized by steepest descent algorithm to eliminate the possible hard contacts from the initial structure until tolerance of 2500 kJ/mol. The energy-minimized system was subjected to 500 ps equilibration under NVT ensembles by using a V-rescale thermostat at 300 k temperature. In the next step, 1000 ps of NPT equilibration was done at 1 bar using Parrinello-Rahman barostat. Finally, the equilibrated systems were subjected to 30 ns production run at 300 K temperature and 1 bar pressure. LINCS algorithm was applied to constrain the bonds (Kumar et al., 2017) while; Particle Mesh Ewald was used to calculate the long-range electrostatic interactions with a cut-off distance of 1.2 nm (Steindl & Langer, 2004). The MD simulations were done in periodic boundary conditions. GROMACS tools, DS and visual molecular dynamics software were used to analyze the trajectories.

2.5. Binding free energy calculations

Molecular mechanics/Poisson-Boltzmann Surface Area (MM/ PBSA) was used to compute the binding free energy as described previously (Bavi et al., 2016, 2017; Kumar et al., 2019). For computing binding free energy, 30 snapshots of protein-ligand complex were chosen evenly from 0 to 30 ns of molecular dynamics simulation trajectories as per the previous studies (Bavi et al., 2019; Hou et al., 2011). MM/PBSA algorithm calculates different energy parameters by using the same snapshots (Hou et al., 2011; Vorontsov & Miyashita, 2011). The binding interaction between protein and ligand is calculated in three terms such as electrostatic contribution ($\Delta E_{\text{ele}}$), van der Waals contribution ($\Delta E_{\text{vdw}}$) and the solvation contribution ($\Delta E_{\text{sol}}$).

3. Results and discussion

The emergence of highly pathogenic coronavirus, causing a severe acute respiratory infection is rapidly spreading throughout the world (Dhama et al., 2020; Sharma et al., 2020). Unfortunately, to date, no drug or vaccine is available to inhibit the pathogenic effect of coronavirus. Thus, the development of safe and effective drug molecules is important to control the disease and its spreading (Li & De Clercq, 2020). Therefore, non-structural viral proteins act as an attractive target for drug discovery (Zumla et al., 2016). The normal drug discovery is time-consuming (Stromgaard et al., 2016). Thus, drug repositioning, also known as repurposing strategies, is effective in identifying an antiviral agent to combat this disease (Li et al., 2016). The RdRp and Nsp15 are well studied non-structural proteins of viruses and acts as an attractive target for antiviral drug discovery. In the present study, we used these targets for the identification of potential inhibitors using a drug repurposing strategy.
Table 1: Molecular docking results of top 10 ligand molecules of RdRp with binding free energy and their molecular interactions.

| Compound structure and ZINC ID | Binding Free Energy | H-Bonding interactions (Conventional H Bond, Carbon-H Bond) | Hydrophobic interactions (Pi-Sigma, Pi-Alkyl, Alkyl) | Other interactions (Pi-Cation, Pi-Anion, Pi-Lone Pair, Salt Bridge, Halogen) |
|-------------------------------|---------------------|---------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------|
| ZINC000014768621 (Chlorhexidine) | -10.11              | ASP618, SER759, ASP760                                        | ALA688, LY5621, CY5622                               |                                                                 |
| ZINC000066166864 (Alectinib)    | -9.6                | TYR619, THR80, ARG624, THR540                                | TYR456, CY5622, ALA558                              | MET542, ARG624, THR656                                          |
| ZINC1481815 (Exjade)            | -9.2                | ARG553, ARG555, ARG624, THR576                                | VAL667, MET542, ALA558                              | ASP623, THR556                                                 |
| ZINC000011677837 (Eliquis)      | -8.91               | LYS676, THR680                                              | MET542, MET566, ALA558                              | ARG624, ASP623, MET542                                         |
| ZINC000043206370 (Niraparib)    | -8.74               | ARG631, SER682, GLY679                                       | MET542, MET566, CY6622, LYS676, ALA558              | ASP623                                                         |
| ZINC000011679756 (Eltrombopag)  | -8.66               | LYS621, ASP452, THR680                                      | CY5622, ARG553, ARG624                              |                                                                 |
| ZINC000001530886                |                     |                                                               |                                                     |                                                                 |
3.1. Structural modeling of RdRp and Nsp15

The homology models of RdRp and Nsp15 were predicted using Modeller 9.23, as discussed in the method section. The stereochemical quality of the RdRp and Nsp15 model was performed using various tools. The Ramachandran plot analysis of the RdRP model shows that 92.1% of residues were in the favored region, and 7.6% residues were in the allowed region (Laskowski et al., 1993). Whereas 82.4% of residues of the Nsp15 model falls in the favored region and 15.5% residues are in the allowed region (Supporting Information Fig. S1). Also, the overall G-factor and main-chain parameters indicate a better quality model, as depicted in Supporting Information Fig. S2.

Furthermore, the Z-score of the model is calculated using the ProSA-Web server. The Z-score is indicative of the model quality and measures the deviation of the total energy of structure (Wiederstein & Sippl, 2007). The Z-score of RdRp and Nsp15 was –12.79 and –7.6, respectively, as showed in Supporting Information Fig. S3. These results revealed that predicted models of RdRp and Nsp15 are good in terms of stereochemical quality and well-validated geometry. The RdRp and Nsp15 models were further used for the docking study.

3.2. Virtual screening of compound against RdRp and Nsp15

The ligand dataset of 3277 compounds was subjected to virtual screening against RdRp and Nsp15 protein targets of COVID-19. The virtual screening was performed using the autodock tool implemented in PyRx (Dallakyan & Olson, 2015).

3.2.1. Interaction analysis and selection of top leads as RdRp inhibitors

The screening of the ligand dataset was performed against a structural model of RdRp of COVID-19. The RdRp catalyzes RNA synthesis from the RNA template crucial for viral genome replication and transcription process. Furthermore, the 3D architecture of RdRp was found conserved and similar to the polymerase family of viruses. It is composed of three sub-domains includes finger (residues S397-A581 and K621-G679), palm (residues T582-P620 and T680-Q815) and thumb (residues H816-E920; Figure 1(A); Bruenn, 2003).

The sequence and structural analysis of RdRp from RNA viruses revealed that the RdRp active site is surrounded by seven catalytic motifs A-G distributed within palm and finger...
The obtained docked conformations were ranked based on binding free energy and top 10 lowest binding energy ligand conformations were extracted. The binding free energy of the top 10 ligand conformation ranges from $-10$ to $-9$ Kcal/mol. This indicates that these compounds have a good binding affinity with RdRp. The resulting top 10 ligand conformations were evaluated for its binding mode and molecular interaction with active site residues of RdRp (Table 1). The significant differences have been observed in molecular interactions, binding mode and side-chain orientation between shortlisted top 10 compounds with RdRp (Table 1). Among them, the two compounds having the lowest binding energy observed in the active site of RdRp as compared with other lead molecules as given in Figure 2.

The first compound, namely, Chlorohexidine with binding free energy $-10.11$ Kcal/mol efficiently accommodated in the active site of RdRp and do molecular mimicry of nucleotides in terms of substructure interactions with RdRp residues (Figure 2(A)). Similarly, the second compound Alectinib with binding free energy $-9.6$ Kcal/mol was observed in the catalytic groove of RdRp (Table 1 and Figure 2). The resulting conformation of Chlorohexidine and Alcteinib was evaluated for molecular interactions with active site residues of RdRp.

The Chlorohexidine consists of two 4-chlorophenyl-guanido groups separated by hexane. The 4-chlorophenyl moiety interacts with Asp684 and Ala688 through hydrogen bonding and Pi-sigma interactions, respectively. While the guanido group forms direct hydrogen-bonding interactions with Ser759, Asp760 and Asp 618. Moreover, the Cys622 and
Lys621 make pi-alkyl interactions with hexane and 4-chloro-phenyl group, respectively, as shown in Figure 3(A) and Table 1. Additionally, the RdRp residues Tyr619, Pro620, Asp623, Thr680, Ser682, Thr687 and Asn691 shows van der Waals interaction with Chlorohexidine (Figure 3(A)). The Chlorohexidine occupies active site pocket of RdRp and forms hydrogen bonding, Pi-alkyl and van der Waals interaction with RdRp residues. Further, the bound conformation of Alectinib was analyzed. The Alectinib consist of a substruc-}

ure of four planer ring structure of benzo[b]carbazole-3-carbonitrile shows a slight deviation when compared with Chlorohexidine. Whereas, 4-pyrrolidine-1-yl-piperidine moiety occupies relevant space similar to Chlorohexidine (Figure 3(A)). The variation in binding mode results in altered RdRp residue interaction with Alectinib. The 4-pyrrolidine-1-yl-piperidine moiety forms hydrogen bonding and Pi-alkyl interactions through Tyr619 and Cys622, respectively (Figure 3(B) and Table 1), whereas benzo[b]carbazole-3-carbonitrile core exists as planer conformation interacts with residues Thr680, Arg624, Thr540 through hydrogen bonding. Additionally, RdRp residues Tyr456, Ala558, Met542, Tyr456 and Arg624 show pi interaction with a substructure of Alectinib (Figure 3(B)). Finally, the RdRp complexed with Chlorohexidine and Alectinib were subjected to MD simulation.

3.2.2. Interaction analysis and selection of top leads as Nsp15 inhibitors

Nsp15 is another important non-structural protein specifically cleave RNA at 3' of uridylates, forming a 2', 3'-cyclic phos-

phate product (Fung & Liu, 2019; Bhardwaj et al., 2004). Recently, it has been reported that Nsp15 suppress the activation of host dsRNA sensor, including PKR kinase (Deng
et al., 2017). The active site of Nsp15 is composed of three histidine at positions 234, 242 and 249 located on the activation loop and Lys 289 opposite to histidine on supporting loop (Figure 1(B)). The residue His 234, His242, His 249 and Lys 289 were treated as flexible during docking of Nsp15 (Joseph et al., 2007; Ricagno et al., 2006). The prepared ligand datasets were screened against the active site of Nsp15. The selection of the top 10 ligands from docked

| Compound structure and ZINC ID | Binding energy | H-Bonding interactions (Conventional H Bond, Carbon-H Bond) | Hydrophobic interactions (Pi-Sigma, Pi-Alkyl, Alkyl) | Other interactions (Pi-Cation, Pi-Anion, Pi-Lone Pair, Salt Bridge, Halogen) |
|--------------------------------|---------------|------------------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------------------|
| ZINC000100378061 (Naldemedine) | –10.95        | SER261, ARG257, LYS289                                      | PHE263, LEU254                                      | ASP282, ASP239                                                           |
| ZINC000052955754 (Ergotamine)  | –10.12        | CYS290, ARG257                                             | LEU254, PHE263, LYS289                              | HIS249                                                                   |
| ZINC000003780893 (Simvastatin) | –9.93         | LEU254, ARG257                                             | CYS292, VAL294, ILE820, CYS290, LYS289              | –                                                                        |
| ZINC000001530886                | –9.93         | ARG257, LYS289, CYS290, VAL291, GLY246                    | CYS292, LEU254, HIS249                              | –                                                                        |
| ZINC000003830500 (Cephalexin)  | –9.70         | PRO262                                                     | LYS289, PHE263, HIS249, ILE820, CYS292, CYS290      | ASP282                                                                   |
| ZINC000000538621 (Olmesartan)   | –9.70         | TYR237, ARG257, LYS289                                     | HIS249, PHE263, LEU254, ILE820                      | CYS292                                                                   |
conformations was based on the binding free energy. The binding free energy of the top 10 ligand ranges from $-10.95$ to $-9.4$ Kcal/Mol, as depicted in Table 2. The binding modes of the top 10 compounds were evaluated. The top eight compounds occupied a similar binding site and last two compounds bound different sites than the catalytic region of Nsp15. Even though similar binding mode of top eight leads, but significant variation was observed in the orientation of ligand substructure concerning active site pocket. Subsequently, the top two compounds were evaluated for its binding mode, and molecular interaction. Naldemedine, the top lead molecule, accommodated in the active site pocket of Nsp15 (Figure 4). The octahydromethanobenzofuro isoquinoline moiety was observed near to the activation loop pocket while benzene-oxadiazol in the pocket formed by the supporting loop. The molecular interaction of Naldemedine sub-structures with the key residues of Nsp15 was located on the activation and supporting loop.

Naldemedine formed hydrogen bonding interactions with Ser261, Arg257 and Lys289 of Nsp15 (Joseph et al., 2007; Ricagno et al., 2006). The residues Asp282, Phe263, Asp239, Leu254, Arg 257 and Lys289 show pi interaction with Naldemedine, as shown in Figure 5(A) and Table 1. The active site surrounding residues such as Gly238, Gy247 Ser287, Ser 288, Cys290, Ser293 shows van der Waals interaction with the ligand molecules (Figure 5(A) and Table 1;
The second lead molecule, Ergotamine bound conformation, showed slight variation in the side-chain orientation with respect to Naldemedine binding in the active site of Nsp15 (Figure 4). The hexahydroindolo quinoline structure accommodates in the pocket of a supporting loop while hexahydrooxolopyrrolo-pyrazine moiety was observed in the space between activation and supporting loop (Figure 4(B)). The resulting bound conformation of Ergotamine makes hydrogen bonding interaction with residues Cys290 and Arg257. The residues Lys289, Phe263, His249, Leu254 and Lys289 show pi type interactions with Ergotamine. Furthermore, Val291, Cys292, Ile280, Pro262, shows van der Waals interactions with the sub-structure of Ergotamine (Figure 5(B) and Table 2). Subsequently, MD simulation has been performed on NSP15 complexed with Naldemedine and Ergotamine.

3.3. MD Simulation of selected docked complexes

MD simulation is essential to check stability of predicted interaction between identified ligand molecule and target proteins, selected docked complexes were subjected to atomistic simulation. We selected top 2 complexes for each target protein RdRp and Nsp15 and subjected to 30 ns MD simulation. We determined structural deviation of protein and ligand molecule during simulation time by analysis of each complex with set of standard parameters such as RMSD and root mean square fluctuations (RMSF). Moreover, binding free energy of ligands with protein molecule has been calculated throughout simulation using MM/PBSA method to validate binding affinity of ligand with protein target.
3.3.1. Conformational flexibility and stability analysis of RdRp during MD

To examine the changes in conformational stability of protein-ligand complexes, we calculated RMSD of protein backbone and ligand with respect to initial structure for all simulations. The average RMSD value is relatively low (2.0 Å) throughout simulation time for protein backbone. The average RMSD value of ligand Alectinib and Chlorohexidine is 1.0 Å and 2.0 Å, respectively, as depicted in Figure 6(A). It indicates that the bound conformation of Alectinib is more stable and not deviated from docked region whereas initially Chlorohexidine shows higher value due to conformation rearrangement in active site followed by stable for entire simulation time (Figure 6(A)). On the other hand, RMSD of protein backbone found stable throughout simulation time with small drift and plateaus (Figure 6(A)). The RMSF calculation is helpful to understand protein residue fluctuation during simulation time. There are no significant differences observed in residue fluctuation in both complexes. The higher residues fluctuation observed only at N-terminal and C-terminal regions and loop region (Figure 6(B)). Also, the residues at position 137, 432 and 590 shows major fluctuation due to located on extended loops when compared RdRp-Chlorohexidine with RdRp-Alectinib complex.

3.3.2. Analysis of molecular interaction of RdRp with ligands

The representative conformation from highest populated cluster was extracted for analysis of binding mode and

\[ \text{Figure 5. Molecular interactions between ligand and Nsp15 residues, (A) Left Panel: Nsp15 rendered as flat ribbon with key interacting residues in ball and stick (Green) and Naldemedine (dark purple) of the predicted poses. Right panel: Schematic representation of 2D interaction plot of Nsp15 residues with Naldemedine (magenta). (B) Left Panel: Nsp15 rendered as flat ribbon with key interacting residues in ball and stick (Green) and Ergotamine (tyrian purple) of the predicted poses. Right panel: Schematic representation of 2D interaction plot of Nsp15 residues with Ergotamine (pink).} \]
molecular interaction. The binding mode and interaction of Chlorohexidine and Alectinib with RdRp compared with predicted in docking pose. The Chlorohexidine consists of two 4-chlorophenyl-guanido groups separated by hexane. The noticeable difference has been observed in binding mode and molecular interaction of Chlorohexidine in catalytic groove of RdRp. The hexane chain observed folded in docked pose while it is found as straight chain in simulated structure (Supporting Information Fig. S4A). This conformational rearrangement result into highest plateau observed

Figure 6. (A) RMSD plots of RdRp backbone and ligands during 30 ns MD simulations. (B) RMSF plot of RdRp complexed with Chlorohexidine and Alectinib for entire simulation time. (C) Estimated binding free energy using MM/PBSA method of RdRp complexes throughout simulation time.
in ligand RMSD plot at 1200 PS to 2000 PS followed by stable for entire simulation time (Figure 6(A)). The Chlorohexidine conformational variation leads to alteration in molecular interaction depicted in Figure 7(A). The RdRp residues Arg553, Tyr455 and Lys 500 shows hydrogen bonding and Pi-Alkyl interactions while Asn497, Lys545, Val557 and Ala558 make van der Waal interactions with Chlorohexidine (Figure 7(A)). The significant variation in interaction is due to altered conformation Chlorohexidine in catalytic groove of RdRp.

Similarly, the representative structure of RdRp-Alectinib extracted from simulation for interaction analysis. The binding mode of Alectinib in simulated structure found similar with predicted docked pose (Supporting Information Fig. S4). It is also evident from RMSD of Alectinib found stable for entire simulation time (Figure 6(A)). The RdRp residues Arg553, Tyr455 and Lys 500 shows hydrogen bonding and Pi-Alkyl interactions while Asn497, Lys545, Val557 and Ala558 make van der Waal interactions with Chlorohexidine (Figure 7(A)). The significant variation in interaction is due to altered conformation Chlorohexidine in catalytic groove of RdRp.

Further, the binding free energy of both ligands has been calculating using MM/PBSA method. The snapshot of RdRp and ligand complexes has chosen evenly form MD trajectories for binding free energy evaluation. The favorable ΔG value has been observed for both complexes range from −20 to −140 kJ/mol as depicted in Figure 6(C). However, noticeable difference has been observed in binding free energy values of Chlorohexidine and Alectinib. The average binding free energy for RdRp-Chlorohexidine and RdRp-Alectinib is −25 kJ/mol and −101 kJ/mol, respectively (Figure 6(C)). The observed difference in binding free energy might be due to altered binding mode and conformational variation in Chlorohexidine during simulation time.

Taken together, the Alectinib shows excellent interaction in terms of hydrogen bonding, Pi stacking and van der Waals with RdRp residues. The docked pose and simulated structure show similar binding mode of Alectinib along with conserved molecular interactions. Alectinib binding mode and interactions found conserved and similar to nucleotide-binding in HCV. Structurally catalytic chamber of HCV and COVID-19 is highly conserved as reported in previous studies (Appleby et al., 2015; Elfiky & Azzam, 2020; Jia & Gong, 2019). Conversely, Chlorohexidine docked pose observed in the catalytic groove of RdRp but after simulation significant difference in Chlorohexidine orientation results into altered residue interaction. Thus, based on stability and molecular interaction and binding mode, Alectinib acts as lead molecule to design novel RdRp inhibitor to block the viral replication.
3.3.3. Conformational flexibility and stability analysis of NSP15 during MD

The RMSD value of protein backbone and ligand molecules has been calculated for entire simulation. The average RMSD value of protein backbone is 2.0 Å indicate stability of protein structure (Figure 8(A)). The ligand RMSD values are 1.0 Å and 1.5 Å for Naldemedine and Ergotamine, respectively (Figure 8(A)).

The RMSF plot shows highest fluctuation of terminal regions and loop region of NSP15 (Figure 8(B)). The similar residue fluctuation observed in NSP15-Naldemedine and NSP15-Ergotamine complexes except position 150 to 153 (Figure 8(B)). This region shows more flexibility due to loop region.

Figure 8. (A) RMSD plots of Nsp15 backbone and ligands during 30 ns MD simulations. (B) RMSF plot of Nsp15 complexed with Naldemedine and Ergotamine for entire simulation time. (C) Estimated binding free energy using MM/PBSA method of Nsp15 complexes throughout simulation time.
3.3.4. Analysis of molecular interaction of NSP15 with ligands

The conformational clustering was performed to select representative structure of NSP15 with ligand from simulation run. The NSP15-Naldemedine structure evaluated for binding mode of Naldemedine in simulated structure with reference to its predicted docked pose. The Naldemedine observed in active site pocket of NSP15 formed by activation and supporting loop as depicted in Supporting Information Fig. S4B. However, Naldemedine is slightly displaced and flipped from predicted docked pose results into altered residue interactions in simulated structure as compared with docked pose (Supporting Information Fig. S4B). The interaction of residues Arg257, Lys289, Cys290 and Phe263 with hexahydroindoloquinoline moiety of Ergotamine similar to docked pose (Figure 9(B)). Also, the hexahydrooxolopyrrolo-pyrazine substructure shows Pi-T shaped interaction with residue His234 located on activation loop of NSP15 (Figure 9(B)). This interaction not observed in docked pose due to change in hexahydrooxolopyrrolo-pyrazine substructure orientation of Ergotamine in simulated structure (Figure 9(B)).

On the other hand, the molecular interactions in NSP15-Ergotamine complex the binding position of Ergotamine is similar to docked pose with slight variation. The Ergotamine hexahydroindoloquinoline moiety accommodated in pocket of a supporting loop similar to docked pose. Whereas, hexahydrooxolopyrrolo-pyrazine substructure is observed near activation loop (Supporting Information Fig. S4B) as it present between activation and supporting loop of NSP15 in docked pose (Figure 4(B)). The interaction of residues Arg257, Lys289, Cys290 and Phe263 with hexahydroindoloquinoline moiety of Ergotamine similar to docked pose (Figure 9(B)). Also, the hexahydrooxolopyrrolo-pyrazine substructure shows Pi-T shaped interaction with residue His234 located on activation loop of NSP15 (Figure 9(B)). This interaction not observed in docked pose due to change in hexahydrooxolopyrrolo-pyrazine substructure orientation of Ergotamine in simulated structure (Figure 9(B)).

Furthermore, we calculated binding free energy of NSP15-Naldemedine and NSP15- Ergotamine using MM/PBSA method. The \( \Delta G \) value ranges from \(-300 \) to \(-400 \) kJ/mol as depicted in Figure 8(C). The average binding free energy for Naldemedine and Ergotamine is \(-330 \) and \(-326 \) kJ/mol,
respectively. Thus, no significant energy difference has been observed in Naldemedine and Ergotamine due to similar binding mode and molecular interaction with NSP15.

Overall, the identified top lead molecule Naldemedine and Ergotamine was observed in the catalytic groove of Nsp15. The Naldemedine and Ergotamine shows excellent interaction with active site residues along with the surrounding residues of Nsp15. In addition, only slight variation in binding free energy has been observed between both ligand molecules. Thus, substructure properties and interaction specificities of Naldemedine and Ergotamine useful to design novel NSP15 inhibitor which will interfere with RNA cleavage and trigger an elevated interferon response and PKR dependent apoptosis. Interestingly, most of identified interacting residues contribute to the interaction with another monomer of Nsp15. Thus, identified ligands may play a dual role as an inhibitor and also interfere with its interaction with other monomers.

In summary, the two non-structural proteins, the RdRp and Nsp15 play a crucial role in viral replication and RNA processing used in our study. We have performed homology modeling, virtual screening technique to selected potential lead molecule inhibitors. Subsequently, selected top complexes of RdRp and Nsp15 with identified lead molecules subjected to MD simulations. The promising compound such as Alectinib for RdRp while Naldemedine and Ergotamine for NSP15 were successfully identified which will act as a lead inhibitor for RdRp and Nsp15. The identified lead molecules lodged in the catalytic groove of enzymes and form hydrogen bonding as well as pi-pi, pi-sigma, pi-alkyl and vdW interactions with non-polar residues of the targets. As discussed earlier, most of the identified interactions are conserved and similar to the previous substrate and inhibitor interaction with these targets. Our study gives an important structural explanation of the promiscuity and specificity of ligand substructure necessary to inhibit the activity of RdRp and Nsp15. The identified lead inhibitors open up possibilities for designing potent and selective inhibitor against RdRP and Nsp15.

4. Conclusion

Considering the global health emergency and lack of effective treatment available, drug repurposing is the only option of choice. Under the current adverse situation, we employed a series of in silico drug repurposing screening campaigns against important non-structural proteins RdRp and Nsp15. The Alectinib, Naldemedine and Ergotamine, an FDA approved drug, shows high affinity and crucial molecular interaction with key residues involved in catalysis and interaction of substrate in RdRp and Nsp15. Our MD simulation analysis showed excellent stability of these drugs with active site of target proteins. Thus, considering the severity of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the replication-associated proteins of the coronavirus to expedite the process of drug discovery. Finally, we propose that the identified inhibitors represent a novel lead molecule to design a more effective inhibitor to stop the progress of pathogen.

SHB and A. Karthic are thankful to Amity Institute of Biotechnology, Amity University, Mumbai for infrastructure support. We would like to thank Amity University administrative team for their support to carry out this research in a safe and healthy environment during COVID-19 pandemic. Rohit Bavi is thankful to the University Grants Commission for Dr D. S. Kothari postdoctoral fellowship.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Rohit Bavi http://orcid.org/0000-0003-3167-4131
Vikas Kumar http://orcid.org/0000-0003-4468-3459

References

Ago, H., Adachi, T., Yoshida, A., Yamamoto, M., Habuka, N., Yatsunami, K., & Miyano, M. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. *Structure (London, England)*, 7(11), 1417–1426.

Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W., & Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. *Nucleic Acids Research*, 25(17), 3389–3402. https://doi.org/10.1093/nar/25.17.3389

Appleby, T. C., Perry, J. K., Murakami, E., Barauskas, O., Feng, J., Cho, A., Fox, D., Wetmore, D. R., McGrath, M. E., Ray, A. S., Sofia, M. J., Swaminathan, S., & Edwards, T. E. (2015). Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. *Science (New York, N.Y.)*, 347(6223), 771–775. https://doi.org/10.1126/science.1259210

Barage, S. H., Deobagkar, D. D., & Baladhye, V. B. (2018). Characterization of structural and functional role of selenocysteine in selenoprotein H and its impact on DNA binding. *Amino Acids*, 50(5), 593–607. https://doi.org/10.1007/s00726-018-2543-5

Barage, S., Kulkami, A., Pal, J. K., & Joshi, M. (2017). Unravelling the structural interactions between PKR kinase domain and its small molecule inhibitors using computational approaches. *Journal of Molecular Graphics & Modelling*, 75, 322–329. https://doi.org/10.1016/j.jmgm.2017.06.009

Bavi, R., Kumar, R., Choi, L., & Lee, K. W. (2016). Exploration of novel inhibitors for Bruton’s tyrosine kinase by 3D QSAR modeling and molecular dynamics simulation. *PLoS One*, 11(1), e0147190. https://doi.org/10.1371/journal.pone.0147190

Bavi, R., Kumar, R., Rampie, S., Kim, Y., Kwon, Y. J., Park, S. J., & Lee, K. W. (2017). Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: Application of 3D QSAR and molecular dynamics simulation. *Journal of Receptor and Signal Transduction Research*, 37(3), 224–238. https://doi.org/10.1080/10799893.2016.1212376

Bavi, R., Liu, Z., Han, Z., Zhang, H., & Gu, Y. (2019). In silico designed RNA aptamer against epithelial cell adhesion molecule for cancer cell imaging. *Biochemical and Biophysical Research Communications*, 509(4), 937–942. https://doi.org/10.1016/j.bbrc.2019.01.028

Belouzard, S., Millet, J. K., Licitra, B. N., & Whitaker, G. R. (2012). Mechanisms of coronavirus cell entry mediated by the viral spike protein. *Viruses*, 4(6), 1011–1033. https://doi.org/10.3390/v4061011

Bhardwaj, K., Guarino, L., & Kao, C. C. (2004). The severe acute respiratory syndrome coronavirus Nsp15 protein is an endoribonuclease that prefers manganese as a cofactor. *Journal of Virology*, 78(22), 12218–12224. https://doi.org/10.1128/JVI.78.22.12218-12224.2004
Bressanelli, S., Tomei, L., Roussel, A., Incitti, I., Vitale, R. L., Mathieu, M., De Francesco, R., & Rey, F. A. (1999). Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America, 96(23), 13034–13039. https://doi.org/10.1073/pnas.96.23.13034

Bruenn, J. A. (2003). A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases. Nucleic Acids Research, 31(7), 1821–1829. https://doi.org/10.1093/nar/gkg277

Chan-Yeung, M., & Xu, R.-H. (2003). Template-based protein structure modeling. Methods in Molecular Biology, 2163, 243–250.

Deng, X., Hackbart, M., Mettelman, R. C., O'Brien, A., Mielech, A. M., Yi, G., Kao, C. C., & Baker, S. C. (2017). Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 114(21), E4251–E4260. https://doi.org/10.1073/pnas.1618310114

Deng, X., & Susan, B. (2018). An “Old” protein with a new story: Coronavirus endoribonuclease is important for evading host antiviral defenses. Virusology, 517, 157–163. https://doi.org/10.1016/j.virology.2017.12.024

Deng, X., van Geelen, A., Buckley, A. C., O’Brien, A., Pillatzi, A., Lager, K. M., Faaberg, K. S., & Baker, S. C. (2019). Coronavirus endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses. Journal of Virology, 93(8), e02000-18. 10.1128/JVI.02000-18.

Dhama, K., Khan, S., & Tiwari, R. (2020). Coronavirus disease 2019-COVID-19. Clinical Microbiology Reviews, 33(4), e00028-20.

Elfiky, A. A. (2020). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2020.1761882

Elfiky, A. A., & Azzam, E. B. (2020). Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2020.1758789

Elfiky, A. A., Mahdy, S. M., & Elshemey, W. M. (2017). Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses. Journal of Medical Virolgy, 89(6), 1040–1047. https://doi.org/10.1002/jmv.24736

Elmezayen, A. D., Al-Obaidi, A., Sahin, A. T., & Yelekci, K. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 91, 264–266. https://doi.org/10.1016/j.ijid.2020.01.009

Ibrahim, I. M., Abdelmalek, D. H., & Elfiky, A. A. (2019). GRF78: A cell’s response to stress. Life Sciences, 226, 156–163. https://doi.org/10.1016/j.lfs.2019.04.022

Ivanov, K. A., Hertzig, T., Rozanov, M., Bayer, S., Thiel, V., Gorbalenya, A. E., & Ziebuhr, J. (2004). Major genetic marker of nidoviruses encodes a replacable endoribonuclease. Proceedings of the National Academy of Sciences of the United States of America, 101(34), 12694–12699. https://doi.org/10.1073/pnas.0403127101

Jia, H., & Gong, P. (2019). A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Frontiers in Microbiology, 10, 1495.

Joseph, J. S., Saikatendu, K. S., Subramanian, V., Neuman, B. W., Buchmeier, M. J., Stevens, R. C., & Kuhn, P. (2007). Crystal structure of a monomeric form of severe acute respiratory syndrome coronavirus nsp15 suggests a role for hexamerization as an allosteric switch. Journal of Virology, 81(12), 6700–6708. https://doi.org/10.1128/JVI.02817-06

Kang, H., Bhadrwaj, K., Li, Y., Palanisantthin, S., Sacchettini, J., Guarino, L., Lesick-Rawitz, J. L., & Kao, C. C. (2007). Biochemical and genetic analyses of murine hepatitis virus nsp15 endoribonuclease. Journal of Virology, 81(24), 13587–13597. https://doi.org/10.1128/JVI.00547-07

Kindler, E., Gil-Cruz, C., Spanier, J., Li, Y., Wilhelm, J., Rabouw, H. H., Züst, R., Hwang, M., Vkovski, P., Stalder, H., Marti, S., Habjan, M., Cervantes-Barragan, L., Eliot, R., Karl, N., Gaughan, C., van Kuppeveld, F. J. M., Silverman, R. H., Keller, M., … Thiel, V. (2017). Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathogens, 13(2), e1006195. https://doi.org/10.1371/journal. ppat.1006195

Kirchdoefer, R. N., & Ward, A. B. (2019). Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nature Communications, 10(1), 1–9. https://doi.org/10.1038/s41467-019-10280-3

Krisinell, E., & Henrick, K. (2004). Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallographica D Biological Crystallography, 60(Pt 12 Pt 1), 2256–2268. https://doi.org/10.1107/S0907444904026460

Kumar, R., Bavi, R. J., Ng, M., Arulalaperumal, V., Baek, A., Rampogu, S., Kim, M. O., & Lee, K. W. (2017). New compounds identified through in silico approaches reduce the s-synuclein expression by inhibiting prolyl oligopeptidase in vitro. Scientific Reports, 7(1), 1–14.

Kumar, R., Parameswaran, S., Bavi, R., Baek, A., Son, M., Rampogu, S., Park, C., Lee, G., Zeb, A., Parate, S., Rana, R. M., & Lee, K. W. (2019). Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapies. Journal of Molecular Graphics & Modelling, 88, 92–103. https://doi.org/10.1016/j.jmgm.2018.12.006

Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26(2), 283–291. https://doi.org/10.1107/S0021889892009944

Lesburg, C. A., Cable, M. B., Ferrari, E., Hong, Z., Mannarino, A. F., & Weber, P. C. (1999). Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology, 6(10), 937–943. https://doi.org/10.1038/31305

Li, G., & De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, 19(3), 149–150.

Li, J., Zheng, S., Chen, B., Butte, A. J., Swamiadass, S. J., & Lu, Z. (2016). A survey of current trends in computational drug repositioning. Briefings in Bioinformatics, 17(1), 2–12. https://doi.org/10.1093/bib/bbv020

Journal of Chemical Information and Modeling, 51(1), 69–82. https://doi.org/10.1021/cci100275a
Liu, W., Morse, J. S., Lalonde, T., & Xu, S. (2020). Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem: A European Journal of Chemical Biology, 21(5), 730–738. https://doi.org/10.1002/cbic.202000047

Machitani, M., Yasukawa, M., Nakashima, J., Furuichi, Y., & Masutomi, K. (2020). RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19. Cancer Science. https://doi.org/10.1111/cas.14618

Meshram, R. J., Bagul, K. T., Pawnikar, S. P., Barage, S. H., Kolte, B. S., & Gacche, R. N. (2020). Known compounds and new lessons: Structural and electronic basis of flavonoid-based bioactivities. Journal of Biomolecular Structure & Dynamics, 38(4), 1168–1184. https://doi.org/10.1080/07391102.2019.1597770

Miteva, M. A., Guyon, F., & Tuffery, P. (2010). Frog2: Efficient 3D conformation ensemble generator for small compounds. Nucleic Acids Research, 38(Web Server issue), W622–W627. https://doi.org/10.1093/nar/gkq325

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256

Ricagno, S., Egloff, M.-P., Ulferts, R., Coutard, B., Nurizzo, D., Campanacci, V., Camillau, C., Ziebuhr, J., & Canard, B. (2006). Crystal structure and mechanistic determinants of SARS coronavirus nonstructural protein 15 define an endoribonuclease family. Proceedings of the National Academy of Sciences of the United States of America, 103(32), 11892–11897. https://doi.org/10.1073/pnas.0601708103

Richman, D. D., Whitey, R. J., & Hayden, F. G. (2016). Clinical virology. Wiley.

Sali, A., & Blundell, T. L. (1993). Comparative protein modelling by satisfaction of spatial restraints. Journal of Molecular Biology, 234(3), 779–815. https://doi.org/10.1006/jmbi.1993.1626

Sharma, A., Tiwari, S., Deb, M. K., & Marty, J. L. (2020). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies. International Journal of Antimicrobial Agents, 56(2), 106054. 10.1016/j.ijantimicag.2020.106054.

Shen, M., & Sali, A. (2006). Statistical potential for assessment and prediction of protein structures. Protein Science, 15(11), 2507–2524. https://doi.org/10.1110/ps.062416006

Singhal, T. (2020). A review of coronavirus disease-2019 (COVID-19). Indian Journal of Pediatrics, 87(4), 281–286.

Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L. M., Guan, Y., Rozanov, M., Spaan, W. J. M., & Gorbunova, Y. V., Cambillau, C., Ziebuhr, J., & Canard, B. (2006). Crystal structure and mechanistic determinants of SARS coronavirus nonstructural protein 15 define an endoribonuclease family. Proceedings of the National Academy of Sciences of the United States of America, 103(32), 11892–11897. https://doi.org/10.1073/pnas.0601708103

Steindl, T., & Langer, T. (2004). Influenza virus neuraminidase inhibitors: Generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening. Journal of Chemical Information and Computer Sciences, 44(5), 1849–1856. https://doi.org/10.1021/ci0409844

Sterling, T., & Irwin, J. J. (2015). ZINC 15-Ligand Discovery for Everyone. Journal of Chemical Information and Modeling, 55(11), 2324–2337. https://doi.org/10.1021/acs.jcim.5b00559

Stromgaard, K., Krosgaard-Larsen, P., & Madsen, U. (2016). Textbook of drug design and discovery (5th ed.). CRC Press.

Vorontsov, I. I., & Miyashita, O. (2011). Crystal molecular dynamics simulations to speed up MM/PB(GB)SA evaluation of binding free energies of di-mannose deoxy analogs with PS1G-m4-Cyanovirin-N. Journal of Computational Chemistry, 32(6), 1043–1053. https://doi.org/10.1002/jcc.21683

Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., & Berendsen, H. J. (2005). GROMACS: Fast, flexible, and free. Journal of Computational Chemistry, 26(16), 1701–1718. https://doi.org/10.1002/jcc.20291

Wiederstein, M., & Sippl, M. J. (2007). ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research, 35(Web Server issue), W407–W410. https://doi.org/10.1093/nar/gkm290

Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., Wang, Q., Xu, Y., Li, M., Li, X., Zheng, M., Chen, L., & Li, H. (2020). Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 9(5), 766–788. https://doi.org/10.1016/j.apsb.2020.02.008

Wu, Y., Lou, Z., Miao, Y., Yu, Y., Dong, H., Peng, W., Bartlam, M., Li, X., & Rao, Z. (2010). Structures of EV71 RNA-dependent RNA polymerase in complex with substrate and analogue provide a drug target against the hand-foot-and-mouth disease pandemic in China. Protein & Cell, 1(5), 491–500. https://doi.org/10.1007/s13238-010-0061-7

Zoete, V., Cuendet, M. A., Grosdidier, A., & Michelini, O. (2011). SwissParam: A fast force field generation tool for small organic molecules. Journal of Computational Chemistry, 32(11), 2359–2368. https://doi.org/10.1002/jcc.21816

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, G. F., & Tan, W.; China Novel Coronavirus Investigating and Research Team (2020). A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine, 382(8), 727–733. https://doi.org/10.1056/NEJMa2001017

Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016). Coronavirus - Drug discovery and therapeutic options. Nature Reviews. Drug Discovery, 15(5), 327–347. https://doi.org/10.1038/nrd.2015.37